在HIV-1治疗中药物耐药性基因定型:VIRADAPT随机对照试验
J Durant1, P Clevenbergh, P Halfon
1Department of Infectious Diseases, Archet Hospital, Nice, France.
Lancet (London, England)
|July 7, 1999
概括
基因型耐药性测试显著改善了HIV-1药物失效患者的病毒学反应. 这种方法有助于选择有效的替代疗法,证明其临床实用性.
科学领域:
- * 病毒学 病毒学
- * 传染病 传染病
- * 临床医学 临床医学
背景情况:
- *越来越多的证据将HIV-1耐药性突变与治疗失败联系在一起.
- * 基因型耐药性分析在对不响应患者的指导治疗中的有用性仍未得到充分研究.
- *这项研究评估了基因型耐药性测试的病毒学和免疫学影响.
研究的目的:
- *评估基因型耐药性测试在管理HIV-1治疗失败方面的有效性.
- * 为了比较标准护理和基因型抗性导向治疗之间的病毒学和免疫学结果.
- * 确定耐药性测试对HIV-1RNA病毒载量减少的影响.
主要方法:
- *前性,开放标签,随机对照试验,涉及HIV-1感染患者,并未成功进行组合治疗.
- *患者随机分配到标准护理或以蛋白质酶和逆转录酶基因耐药性突变为指导的治疗.
- *主要终点是HIV-1RNA病毒载量的变化,根据治疗意图进行分析.
主要成果:
- *与对照组相比,基因型组在3个月 (-1.04日志) 和6个月 (-1.15日志) 后的HIV-1RNA病毒载荷的平均减少显著更大 (分别为-0.46日志和-0.67日志).
- *在3个月后,基因型组中较高比例的患者达到无法检测的HIV-1RNA水平 (29%对14%).
- * 在这两组中,治疗耐受性良好,因毒性而对药物进行最小的修改.
结论:
- * 基因型耐药性测试在选择替代HIV-1疗法时为病毒学反应提供了显著的好处.
- *基因型耐药性测试是帮助治疗失败的患者进行临床决策的宝贵工具.
- *需要进一步的研究来探索基因型耐药性测试在临床实践中的更广泛应用.
相关概念视频
Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...


